NASDAQ · Analyst Forecast

20/20 Biolabs, Inc. (AIDX) Stock Forecast & Price Target

$0.19 NASDAQ: AIDX Market Cap $2.51M

Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 12, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)

Revenue and earnings estimates published by analysts covering 20/20 Biolabs, Inc. (AIDX), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For 20/20 Biolabs, Inc., analysts forecast revenue rising from $2.62M in 2026 to $61.58M in 2030; the average estimate for 2030 earnings per share is −$0.41; 1 analyst contribute to these figures. These are forecasts published by analysts, not results.

Analyst price targets

MeasureValue
Current priceWhat the share trades at now.$0.19
Consensus targetThe average of the price targets analysts have published.$5.00
Median targetThe middle target, less affected by a single outlier.$5.00
Highest targetThe most optimistic published target.$5.00
Lowest targetThe most pessimistic published target.$5.00
Difference from priceHow far the consensus target sits from today’s price.+2531.6%

A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.

Revenue forecast (USD)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

YearLowAverageHighAnalysts
2026$2.62M$2.62M$2.62M1
2027$5.77M$5.77M$5.77M1
2028$8.89M$8.89M$8.89M1
2029$19.11M$19.11M$19.11M1
2030$61.58M$61.58M$61.58M1

Earnings per share forecast

YearLowAverageHighAnalysts
2026−$0.52−$0.52−$0.521
2027−$0.38−$0.38−$0.381
2028−$0.47−$0.47−$0.471
2029−$0.52−$0.52−$0.521
2030−$0.41−$0.41−$0.411

20/20 Biolabs, Inc. (AIDX) forecast — frequently asked questions

What is the analyst price target for 20/20 Biolabs, Inc.?

Analysts covering 20/20 Biolabs, Inc. (AIDX) have a consensus price target of $5.00, 2531.6% above the current price of $0.19. Published targets range from $5.00 to $5.00. A price target is a forecast, not a measure of value, and targets are revised often.

What are analysts forecasting for 20/20 Biolabs, Inc.'s earnings?

The average analyst estimate for 20/20 Biolabs, Inc. (AIDX) earnings per share in 2030 is -0.41, with individual estimates between -0.41 and -0.41.

How much revenue is 20/20 Biolabs, Inc. expected to make?

Analysts forecast 20/20 Biolabs, Inc. (AIDX) revenue of $61.58M in 2030, based on 1 published estimates.

How many analysts cover AIDX?

1 analyst contribute estimates for 20/20 Biolabs, Inc. (AIDX). Thin coverage makes an average less reliable.

Analyst forecasts for other Medical - Care Facilities stocks

HCA forecastTHC forecastEHC forecastDVA forecastENSG forecastUHS forecastCHE forecastLFST forecastOPCH forecastHIMS forecastAll Medical - Care Facilities stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.